AKR1C3 and hepatocellular carcinoma: Wu et al. noted that the AKR1C3-dependent increase in lipid droplet accumulation protects cancer cells from sorafenib-induced mitochondrial lipotoxicity and induces adaptation to sorafenib in hepatocellular carcinoma 33.